Lilly angles for arthritis blockbuster

Lilly angles for arthritis blockbuster

Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis—a market poised to grow to $80 billion by 2020. Lilly submitted

(Visited 1 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.